
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Shelhigh, Inc. has agreed to stop distributing its implantable medical devices, used in heart surgery and other procedures, until the company brings its production processes in line with Food and Drug Administration (FDA) standards [more].






